Pharma Blog Watch

Ortho Biotech Submits sNDA for Doxil (Pharma Gazette)
In her blog, Gloria Gamat writes that Ortho Biotech has submitted a supplemental new drug application (sNDA) for Doxil (doxorubicin HCl liposome injection) for use in combination with Velcade (bortezomib) to treat multiple myeloma. "Doxil is currently indicated for the treatment of ovarian cancer patients whose disease has progressed or recurred after platinum-based chemotherapy, while Velcade is the market leader in relapsed multiple myeloma."